Adventris
- Biotech or pharma, therapeutic R&D
Adventris is developing therapeutic cancer vaccines. Our vaccine platform overcomes challenges of targeting poorly immunogenic oncogenes, with our lead “off-the-shelf” vaccine directed against KRAS —the most common oncogene. Our therapeutic vaccine covers the 5 most common KRAS mutations – G12D, G12V, G12C, G12R, and G12A. We plan to nominate our development candidate in 2025 and anticipate dosing our first patient in 2027.
Our initial indication is the adjuvant treatment of resected PDAC, with future expansion into other KRAS-driven cancers.
Adventris is built by a team of world-class cancer vaccine researchers, and utilizes a core antigen-engineering technology that was developed at Johns Hopkins. Our CSO, Dr. Mark Yarchoan, and Scientific Co-Founder, Dr. Liz Jaffee, are leaders in immuno-oncology. Our CEO, Jen Herbach, brings over a decade of experience in biotech company building. Key advisors include Dr. Cathy Wu (Dana-Farber) and Dr. Andrew Allen (CEO/Co-Founder Gritstone).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}